Endocyte Q3

|About: Endocyte, Inc. (ECYT)|By:, SA News Editor

Endocyte (NASDAQ:ECYT) Q3 results ($M): Net loss: (23.3) ( -84.9%).

Upcoming milestones:

IND for Phase 1 study of EC17/CAR-T therapy in osteosarcoma (this quarter).

Completion of merger with Novartis (NYSE:NVS): H1 2019.

Analysis of rPFS in VISION study: late 2019.

Subscribe for full text news in your inbox